Background:
International recommendations for the management of axial spondyloarthritis including ankylosing spondylitis (AS) suggest a BASDAI level of disease activity of ≥4 to indicate treatment with biologics. Other cut-offs have rarely been studied so far. Objectives: Therefore, we were interested to learn about the level of disease activity used in daily routine to start anti-TNF therapy. Methods: In a posthoc subanalysis of the non-interventional, prospective, study GO-NICE that has been performed in a real life setting in Germany we used data from biologic naïve patients with established AS to study the initial BASDAI values before the start of therapy with Golimumab 50mg SC once monthly. Established standardized outcome measures were used. Results: Out of a total of 543 AS-patients (pts.) documented in 126 German centers, 244 biologic-naïve pts. were eligible. A total of 134 pts. (54.9%) completed the 24 month observational period. The majority of pts. (70.5%), had a BASDAI ≥4 (group (gr.).1), while 14.3% had a BASDAI of ≥2.8 -<4 (gr.2) and 15.1% even had a BASDAI <2. 8 (gr.3, Table) . The patient demographics did not differ much between these 3 groups, the proportion of males was numerically somewhat lower in gr.1. The proportion of pts. with an elevated CRP was highest in gr.2 at BL. The BASDAI in gr.1,2 and 3 was initially 5.9±1.3, 3.4±0.4 and 2.0±0.8, dropped significantly to 2.2*±2.0, 1.9*±1.2 and 1.0±1.2 within 3 months (*p<0.0001 vs. BL), and decreased significantly (p<0.005) to 2.2±1.7, 1.9±1.7 and 1.4±1.0 at month 24, respectively ( fig.) .The BASDAI 50% improvement was 68.8%, 44.8%, and 45.2% at month 3, and increased to 84.9%, 61.9%, and 55.0% at month 24, respectively.
Conclusions:
The most interesting observation of this real life study and posthoc analysis is certainly that almost a third of the pts. were included in the study who did not reach the recommended BASDAI cut-off of ≥4. Furthermore the data show that the patients with a BASDAI 2.8 -<4 seem to have significant benefit of anti-TNF treatment, while this was not really the case with in pts. with a BASDAI <2.8. This finding should lead to a reevaluation of the established BASDAI cut-off of ≥4. Future studies should also evaluate the performance of an ASDAS cut-off. Background: Secukinumab has been shown to significantly improve symptoms of psoriatic arthritis (PsA) 1 and ankylosing spondylitis (AS) 2 in numerous phase III studies. Still, as randomized, controlled, clinical trials often limit their patients to a very strict and selected group, further data on real world evidence is necessary to assess efficacy in a broader patient group. Objectives: To evaluate baseline characteristics regarding demographics, disease activity and comorbidities in patients with active PsA or AS in daily practice treated with secukinumab in Germany. Methods: AQUILA, a non-interventional, multi-center, 52-week study enrolling 2000 patients with active PsA or AS. Patients are documented as treated in clinical practice. Here, we will report the baseline characteristics of a subgroup of 347 patients who have been enrolled in the study. At baseline patient's health status, selected comorbidities and disease history was assessed using routine parameters (among others: CRP, joint count, BASDAI). Furthermore, overall disease activity and quality of life has been documented using ASAS-HI (AS) and PsAID-12 item (PsA). Results: 108 AS-and 239 PsA-patients were included, majority of AS patients were male, in PsA the majority was female. Previous bDMARD exposure was high in both groups, percentage of NSAID and cDMARD exposure varied (Tab). For PsA patients elevated CRP (Tab) and a high number of tender (8.4) and swollen joints (4.4) was reported. Assessed comorbidities included coronary heart disease (9.7%), stroke (2.5%), heart failure (2.9%) and depression (13.4%). Effect of PsA on patient's life at baseline was reported via PsAID-12 item with a mean score of 5.0 (±2.2). AS patients enrolled in this trial had a high disease activity with a mean BASDAI of 5.5 (±2.0) and elevated CRP (Table) . Considered comorbidities were coronary heart disease (4.6%), stroke (0%), heart failure (0.9%) and depression (12%). Patient's impairments due to AS were assessed at baseline with the ASAS-HI, reporting a mean score of 8.1 (±3.6).
The baseline characteristics of the population are comparable with Data was extracted using a form developed for this specific purpose. The quality of the studies was assessed based on CEBM Oxford. Clinical response in patients who switched to a second bDMARD was determined and compared with the one achieved after receiving the first bDMARD (a TNFi in all cases). Results are shown as median (range) and relative frequencies (%). Results: In total, 7 studies out of 1506 retrieved citations were included. All studies included patients with ankylosing spondylitis (AS). The study design was prospective observational (n=3), retrospective observational (n=2), open-label trial (n=1) and post-hoc analysis from two RCTs (n=1). The level of evidence for all the studies was 4. In these studies, a total of in 4678 patients received a first bDMARD and 1198 patients switched to a second bDMARD (a TNFi in all cases except in 51 patients that switched to secukinumab). Baseline characteristics of patients included in the studies were: 41 (38-44) years old, 67% (64-74) males, 78% (74-89) HLA-B27+ and BASDAI before switching 6.2 (5.3-6.5). The most frequent reason to switch bDMARD was inefficacy, followed by intolerance/adverse events. Median (range) time to assess response after switching was 6 (3-12) months. The criteria to define clinical response were heterogeneous. BASDAI50 was employed in four studies and the percentage of patients who achieved this response after the first and the second bDMARD for each study was: (63% vs 41%), (50% vs 28%), (54% vs 37%), (72% vs 56%), respectively. The response for the other three studies was based on different definitions, being as follows: BASDAI <4 (83% vs 78%), ASAS20 response (67% vs 48%) and retention rate after one year (65% vs 60%). The reason to switch bDMARD (intolerance or inefficacy) was not found as a significant predictor of treatment response in most of the studies. In addition, two studies reported data (n=137 and 11 patients) to evaluate the efficacy of switching to a third bDMARD (TNFi in both cases). The percentage of patients who responded (BASDAI50) to the third TNFi was 30% and 52%, respectively.
In patients with AS who do not respond to a first TNFi, switching to another bDMARD (either a TNFi or secukinumab) is efficacious in a considerable number of patients (30-50%). However, the clinical response after receiving a second bDMARD is lower to the one experienced after the first TNFi. Published data for switching to a third bDMARD is very limited. Background: Rapid and sustained improvements in the signs and symptoms of ankylosing spondylitis (AS) have been reported with secukinumab, a fully human anti-IL-17A mAb, over the first 2 years (yrs) in the Phase 3 MEASURE 1 trial.
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Objectives: To report efficacy and safety of secukinumab through 3 yrs in an extension trial (NCT01863732) to the core MEASURE 1 trial. Methods: After the 2-yr core trial, patients (pts) Figure) . Similar trends were observed regardless of prior anti-TNF use (Table) . Across the treatment period (secukinumab exposure [mean±SD] : 964.3±372.1 days), exposure-adjusted incidence rate with secukinumab for serious infections, Crohn's disease and malignant/unspecified tumours was 1.1, 0.5 and 0.5 per 100 pt-yrs, respectively. e Evaluable data available in n=70 and 75 pts (naïve) and n=16 and 23 pts (IR) in the secukinumab IV→150mg and IV→75mg groups, respectively. # Observed data provided for reference. IV, pts received secukinumab 10mg/kg i.v. loading at baseline, Wks 2 and 4; N, number of pts in the extension trial.
Conclusions: Secukinumab provided sustained efficacy in signs/symptoms and physical function in pts with active AS over 3 yrs. Secukinumab was well tolerated with a favorable safety profile consistent with that reported previously. 
